Bringing global clinical trials closer to patients

The expanding scope and complexity of global clinical research

Clinical research activity now spans every region of the world. At the same time, the nature of clinical research has become far more complex.

Trials increasingly involve advanced therapy medicinal products, novel delivery systems and targeted treatments for rare diseases affecting small, geographically dispersed patient populations. Sponsors are also adopting new study designs, including adaptive and virtual trials, along with more sophisticated endpoints and diagnostic tools. Greater emphasis on enrolling diverse patient populations has added further operational considerations.

These shifts place significant operational pressure on clinical sites. Studies often require coordination across numerous sites and countries while managing increasingly intricate protocols and data requirements. Recruitment and retention have become more difficult, and costs have climbed.

As clinical trials continue to become increasingly more complex, geographically distributed and difficult to enroll, sponsors need site network partners that offer more than access to locations. As such, the clinical research industry has turned to integrated global site networks.

Effective global site networks combine operational consistency, local clinical relationships, early feasibility insight and flexible patient access strategies to support efficient study execution across regions. By linking multiple clinical sites through shared operational standards, governance structures and data systems, these networks allow sponsors to manage multi-site studies more efficiently while maintaining consistency in study conduct and data quality.

Standardization without sacrificing local relevance

As site networks become more central to clinical development, sponsors must evaluate them beyond their geographic footprint. Scale alone does not ensure successful execution.

An effective global site network partner should combine standardized processes, strong quality oversight, proven site relationships, therapeutic expertise and the flexibility to adapt study execution to local clinical realities.

Each region has its own regulatory landscape, clinical infrastructure, physician referral patterns and patient access dynamics. A strong network partner should understand these differences and help sponsors select sites based on therapeutic expertise, patient availability, investigator experience and local healthcare relationships – not just country or cost.

The most effective global site networks combine centralized coordination with local clinical engagement. Shared operating standards provide consistency, while site-level expertise adapts execution to the realities of each patient population and healthcare community.

Connecting clinical research with everyday patient care

Patient access depends heavily on local clinical relationships. Even when a trial is part of a global development program, patients often learn about research opportunities through physicians and healthcare providers they already know and trust.

Relationships with local physicians, specialists, advocacy groups and community organizations make clinical research more accessible and more familiar. Local providers identify patients who may benefit from investigational therapies while continuing to provide ongoing care. This preserves the physician-patient relationship while creating a pathway into research participation.

For rare diseases that affect small, geographically dispersed patient populations, decentralized capabilities may extend recruitment, screening and follow-up beyond the immediate vicinity of individual research locations. A concierge-style approach combines centralized recruitment with decentralized clinical services, including virtual conversations, electronic consent, coordination with existing healthcare providers, home healthcare solutions and travel support.

This approach allows sponsors and sites to reach deeper into communities and seek appropriate patients rather than only those who happen to live near a study location. It also enables expanded access to diverse patient populations in rural or underserved areas.

Prague as a central european early-phase hub

The Prague, Czech Republic site within the Trialmed network illustrates how a regional hub supports broader European development strategies.

The site has operated as a late-phase clinical research center since 2018 and has conducted approximately 30 studies to date. Its expansion to include dedicated Phase I capabilities positions Prague as a fully integrated clinical research center capable of supporting studies across multiple stages of development.

The facility includes a dedicated 15-bed Phase I clinical research unit designed to support early development programs, including first-in-human studies, multi-cohort trials and other complex early-phase protocols. Prague offers access to a strategically located Central European research center with strong clinical expertise, relatively lower operating costs and less competition for early-phase trial capacity than many larger Western European and U.S. markets.

Sponsors conducting early-phase studies in Prague may also be able to scale programs into additional Trialmed-affiliated sites across Central and Eastern Europe as development progresses, creating a pathway for expanding enrollment, accessing additional patient populations and supporting later-stage development.

Offering local insight with global scale

The growing complexity of clinical research has made site network selection a strategic decision. Sponsors need networks capable of combining operational consistency, local clinical relationships, therapeutic expertise and flexible patient access strategies across multiple regions.

Networks that align global execution with local clinical reality will be best positioned to support efficient studies, high-quality data generation and broader access to clinical research.